BeiGene vs ImCheck Therapeutics
BeiGene vs ImCheck Therapeutics, compared side by side on 16 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: BeiGene is on 64/100 and ImCheck Therapeutics on 60/100.
Where each one leads
BeiGene
- our overall score: 64/100 against 60/100
- agent readiness: 50/100 against 34/100
- domain rating: 68/100 against 37/100
- funding raised: $358M against $164M
ImCheck Therapeutics
Leads on none of the measures we hold for both companies.
At a glance
| Measure | BeiGene | ImCheck Therapeutics |
|---|---|---|
| What it is | A global oncology company developing and commercializing innovative cancer treatments. | ImCheck Therapeutics is a clinical-stage immuno-oncology company developing novel antibody therapies. |
| Category | Biotech, MedTech, HealthTech, Genomics | Biotech, MedTech, HealthTech, Drug Discovery |
| Sells toBusiness model | B2B | B2B |
| Offering | Platform | Biotech |
| Founded | 2010 | 2015 |
| Headquarters | Cambridge, United States | Marseille, France |
| Status | Active | Active |
Size, funding and growth
| Measure | BeiGene | ImCheck Therapeutics |
|---|---|---|
| Employees | Not published | 47 |
| Open roles | 100 | Not published |
| Total funding | $358M | $164M |
| Latest round | Secondary Offering | Not published |
| Valuation | $15B | Not published |
| LinkedIn followers | Not published | 11,647 |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | BeiGene | ImCheck Therapeutics |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 64/100 | 60/100 |
| Traction | 40/100 | 57/100 |
| Team | 30/100 | 70/100 |
| Community | Not published | 15/100 |
| Search visibility | 17/100 | 22/100 |
| Quality | 88/100 | 68/100 |
| Agent readinessHow well an AI agent can read and act on the site | D (50/100) | F (34/100) |
| Domain ratingLink authority, 0-100 | 68/100 | 37/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | BeiGene | ImCheck Therapeutics |
|---|---|---|
| Hosting | Not detected | Self Managed |
| CDN | Cloudflare | Not detected |
| CMS | WordPress | Not detected |
| Frameworks | Jquery, Tailwind CSS, Bootstrap | Jquery, Tailwind CSS, Bootstrap |
| Analytics | Not detected | Google Analytics 4 |
BeiGene vs ImCheck Therapeutics: common questions
Which is better, BeiGene or ImCheck Therapeutics?
On our 0-100 score BeiGene rates higher (64/100 against 60/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 16 data points above: read the rows that match what you are buying for.
How do BeiGene and ImCheck Therapeutics compare on the numbers?
BeiGene leads on our overall score (64/100 against 60/100), agent readiness (50/100 against 34/100), domain rating (68/100 against 37/100), funding raised ($358M against $164M).
Read the full BeiGene review and pricing or the ImCheck Therapeutics review and pricing. You can also browse other BeiGene alternatives we track.